231 related articles for article (PubMed ID: 34125126)
1. Cerebrospinal fluid lipidomics for biomarkers of Alzheimer's disease.
Byeon SK; Madugundu AK; Jain AP; Bhat FA; Jung JH; Renuse S; Darrow J; Bakker A; Albert M; Moghekar A; Pandey A
Mol Omics; 2021 Jun; 17(3):454-463. PubMed ID: 34125126
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid neutral lipids predict progression from mild cognitive impairment to Alzheimer's disease.
Dakterzada F; Jové M; Huerto R; Carnes A; Sol J; Pamplona R; Piñol-Ripoll G
Geroscience; 2024 Feb; 46(1):683-696. PubMed ID: 37999901
[TBL] [Abstract][Full Text] [Related]
3. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
4. Lipidomic alterations in lipoproteins of patients with mild cognitive impairment and Alzheimer's disease by asymmetrical flow field-flow fractionation and nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry.
Kim SH; Yang JS; Lee JC; Lee JY; Lee JY; Kim E; Moon MH
J Chromatogr A; 2018 Sep; 1568():91-100. PubMed ID: 30007793
[TBL] [Abstract][Full Text] [Related]
5. Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer's disease subjects.
Wood PL; Barnette BL; Kaye JA; Quinn JF; Woltjer RL
Acta Neuropsychiatr; 2015 Oct; 27(5):270-8. PubMed ID: 25858158
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease.
Wang H; Dey KK; Chen PC; Li Y; Niu M; Cho JH; Wang X; Bai B; Jiao Y; Chepyala SR; Haroutunian V; Zhang B; Beach TG; Peng J
Mol Neurodegener; 2020 Jul; 15(1):43. PubMed ID: 32711556
[TBL] [Abstract][Full Text] [Related]
7. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
8. Lipidomic Network of Mild Cognitive Impairment from the Mayo Clinic Study of Aging.
Wang X; Bui H; Vemuri P; Graff-Radford J; Jack CR; Petersen RC; Mielke MM
J Alzheimers Dis; 2021; 81(2):533-543. PubMed ID: 33814434
[TBL] [Abstract][Full Text] [Related]
9. Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach.
Begcevic I; Brinc D; Brown M; Martinez-Morillo E; Goldhardt O; Grimmer T; Magdolen V; Batruch I; Diamandis EP
J Proteomics; 2018 Jun; 182():12-20. PubMed ID: 29684683
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimer's Disease and Inflammation at the Pre- and Early Stages of Dementia.
Teitsdottir UD; Halldorsson S; Rolfsson O; Lund SH; Jonsdottir MK; Snaedal J; Petersen PH
J Alzheimers Dis; 2021; 81(1):231-244. PubMed ID: 33814423
[TBL] [Abstract][Full Text] [Related]
11. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
[TBL] [Abstract][Full Text] [Related]
12. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR
Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986
[TBL] [Abstract][Full Text] [Related]
13. Performance of Validated MicroRNA Biomarkers for Alzheimer's Disease in Mild Cognitive Impairment.
Sandau US; Wiedrick JT; Smith SJ; McFarland TJ; Lusardi TA; Lind B; Harrington CA; Lapidus JA; Galasko DR; Quinn JF; Saugstad JA
J Alzheimers Dis; 2020; 78(1):245-263. PubMed ID: 32955460
[TBL] [Abstract][Full Text] [Related]
14. Relationship between Plasma Lipid Profile and Cognitive Status in Early Alzheimer Disease.
Peña-Bautista C; Álvarez-Sánchez L; García-Lluch G; Raga L; Quevedo P; Peretó M; Balaguer A; Baquero M; Cháfer-Pericás C
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791355
[TBL] [Abstract][Full Text] [Related]
15. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
[TBL] [Abstract][Full Text] [Related]
16. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
17. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.
Khoonsari PE; Shevchenko G; Herman S; Remnestål J; Giedraitis V; Brundin R; Degerman Gunnarsson M; Kilander L; Zetterberg H; Nilsson P; Lannfelt L; Ingelsson M; Kultima K
J Alzheimers Dis; 2019; 67(2):639-651. PubMed ID: 30614806
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid lipidomics: effects of an intravenous triglyceride infusion and apoE status.
Hanson AJ; Banks WA; Bettcher LF; Pepin R; Raftery D; Craft S
Metabolomics; 2019 Dec; 16(1):6. PubMed ID: 31832778
[TBL] [Abstract][Full Text] [Related]
19. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
